Azerbaijan vs Bolivia: Statin use vs. average non-HDL cholesterol levels
Azerbaijan
3.3
in 2018
Bolivia
3.3
in 2018
Azerbaijan rank
95th
Bolivia rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Azerbaijan
- Bolivia
How they compare
Azerbaijan currently reports 3.3 against 3.3 in Bolivia, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Azerbaijan ahead.
Azerbaijan ranks 95th and Bolivia ranks 95th of 191 countries.
Across the 4 decades both report, Azerbaijan averaged higher in 1 and Bolivia in 2.
Head to head by decade
| Decade | Azerbaijan | Bolivia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.4 | 3.26 | 0.14 | Azerbaijan |
| 1990s | 3.32 | 3.35 | 0.03 | Bolivia |
| 2000s | 3.3 | 3.33 | 0.03 | Bolivia |
| 2010s | 3.3 | 3.3 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Azerbaijan or Bolivia?
- Azerbaijan, at 3.3 against 3.3 in Bolivia as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Azerbaijan and Bolivia?
- 0, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Bolivia?
- 39 years are reported by both, from 1980 to 2018.
- How do Azerbaijan and Bolivia rank globally for statin use vs. average non-hdl cholesterol levels?
- Azerbaijan ranks 95th and Bolivia ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.